These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 17652911

  • 1. Evaluation of the pharmacological profile of ramosetron, a novel therapeutic agent for irritable bowel syndrome.
    Hirata T, Keto Y, Funatsu T, Akuzawa S, Sasamata M.
    J Pharmacol Sci; 2007 Jul; 104(3):263-73. PubMed ID: 17652911
    [Abstract] [Full Text] [Related]

  • 2. Effect of ramosetron on conditioned emotional stress-induced colonic dysfunction as a model of irritable bowel syndrome in rats.
    Funatsu T, Takeuchi A, Hirata T, Keto Y, Akuzawa S, Sasamata M.
    Eur J Pharmacol; 2007 Nov 14; 573(1-3):190-5. PubMed ID: 17658508
    [Abstract] [Full Text] [Related]

  • 3. Effects of serotonin 5-HT(3) receptor antagonists on CRF-induced abnormal colonic water transport and defecation in rats.
    Hirata T, Keto Y, Nakata M, Takeuchi A, Funatsu T, Akuzawa S, Sasamata M, Miyata K.
    Eur J Pharmacol; 2008 Jun 10; 587(1-3):281-4. PubMed ID: 18456254
    [Abstract] [Full Text] [Related]

  • 4. Inhibitory effects of ramosetron, a potent and selective 5-HT3-receptor antagonist, on conditioned fear stress-induced abnormal defecation and normal defecation in rats: comparative studies with antidiarrheal and spasmolytic agents.
    Hirata T, Funatsu T, Keto Y, Akuzawa S, Sasamata M, Miyata K.
    J Pharmacol Sci; 2008 Feb 10; 106(2):264-70. PubMed ID: 18296863
    [Abstract] [Full Text] [Related]

  • 5. Pharmacological profile of ramosetron, a novel therapeutic agent for IBS.
    Hirata T, Funatsu T, Keto Y, Nakata M, Sasamata M.
    Inflammopharmacology; 2007 Feb 10; 15(1):5-9. PubMed ID: 17323187
    [Abstract] [Full Text] [Related]

  • 6. Effects of serotonin 5-HT3 receptor antagonists on stress-induced colonic hyperalgesia and diarrhoea in rats: a comparative study with opioid receptor agonists, a muscarinic receptor antagonist and a synthetic polymer.
    Hirata T, Keto Y, Nakata M, Takeuchi A, Funatsu T, Akuzawa S, Sasamata M, Miyata K.
    Neurogastroenterol Motil; 2008 May 10; 20(5):557-65. PubMed ID: 18221252
    [Abstract] [Full Text] [Related]

  • 7. 5-HT3 receptor antagonists. 3. Quinoline derivatives which may be effective in the therapy of irritable bowel syndrome.
    Kishibayashi N, Miwa Y, Hayashi H, Ishii A, Ichikawa S, Nonaka H, Yokoyama T, Suzuki F.
    J Med Chem; 1993 Oct 29; 36(22):3286-92. PubMed ID: 8230119
    [Abstract] [Full Text] [Related]

  • 8. Inhibitory effect of ramosetron on corticotropin releasing factor- and soybean oil-induced delays in gastric emptying in rats.
    Hirata T, Keto Y, Yamano M, Yokoyama T, Sengoku T, Seki N.
    J Gastroenterol Hepatol; 2012 Sep 29; 27(9):1505-11. PubMed ID: 22554268
    [Abstract] [Full Text] [Related]

  • 9. Discovery of a novel 5-HT(3) antagonist/5-HT(1A) agonist 3-amino-5,6,7,8-tetrahydro-2-{4-[4-(quinolin-2-yl)piperazin-1-yl]butyl}quinazolin-4(3H)-one (TZB-30878) as an orally bioavailable agent for irritable bowel syndrome.
    Asagarasu A, Matsui T, Hayashi H, Tamaoki S, Yamauchi Y, Minato K, Sato M.
    J Med Chem; 2010 Nov 11; 53(21):7549-63. PubMed ID: 20931963
    [Abstract] [Full Text] [Related]

  • 10. Comparison between partial agonist (ME3412) and antagonist (alosetron) of 5-hydroxytryptamine 3 receptor on gastrointestinal function.
    Kawano K, Mori T, Fu L, Ito T, Niisato T, Yoshida S, Shiokawa S, Sato Y, Murakami H, Shishikura T.
    Neurogastroenterol Motil; 2005 Apr 11; 17(2):290-301. PubMed ID: 15787949
    [Abstract] [Full Text] [Related]

  • 11. Cilansetron: a new serotonergic agent for the irritable bowel syndrome with diarrhoea.
    Chey WD, Cash BD.
    Expert Opin Investig Drugs; 2005 Feb 11; 14(2):185-93. PubMed ID: 15757394
    [Abstract] [Full Text] [Related]

  • 12. Selective 5-hydroxytryptamine3 (5-HT3) receptor blocking activity of KB-R6933, a novel benzimidazole derivative.
    Ozaki A, Fujishima Y, Sukamoto T.
    Jpn J Pharmacol; 1999 May 11; 80(1):25-32. PubMed ID: 10446753
    [Abstract] [Full Text] [Related]

  • 13. [Pharmacological and clinical profile of ramosetron hydrochloride (Irribow), a novel therapeutic agent for irritable bowel syndrome with diarrhea].
    Hirata T, Funatsu T, Keto Y, Akuzawa S, Akiho H, Nishida A, Sasamata M, Miyata K.
    Nihon Yakurigaku Zasshi; 2009 May 11; 133(5):281-91. PubMed ID: 19443966
    [No Abstract] [Full Text] [Related]

  • 14. Selective corticotropin-releasing factor 1 receptor antagonist E2508 reduces restraint stress-induced defecation and visceral pain in rat models.
    Taguchi R, Shikata K, Furuya Y, Hirakawa T, Ino M, Shin K, Shibata H.
    Psychoneuroendocrinology; 2017 Jan 11; 75():110-115. PubMed ID: 27810704
    [Abstract] [Full Text] [Related]

  • 15. The clinical potential of ramosetron in the treatment of irritable bowel syndrome with diarrhea (IBS-D).
    Min YW, Rhee PL.
    Therap Adv Gastroenterol; 2015 May 11; 8(3):136-42. PubMed ID: 25949526
    [Abstract] [Full Text] [Related]

  • 16. Pharmacological properties of 3-amino-5,6,7,8-tetrahydro-2-[4-[4-(quinolin-2-yl)piperazin-1-yl]butyl]quinazolin-4(3H)-one (TZB-30878), a novel therapeutic agent for diarrhea-predominant irritable bowel syndrome (IBS) and its effects on an experimental IBS model.
    Tamaoki S, Yamauchi Y, Nakano Y, Sakano S, Asagarasu A, Sato M.
    J Pharmacol Exp Ther; 2007 Sep 11; 322(3):1315-23. PubMed ID: 17540858
    [Abstract] [Full Text] [Related]

  • 17. Pharmacological evaluation of a novel corticotropin-releasing factor 1 receptor antagonist T-3047928 in stress-induced animal models in a comparison with alosetron.
    Itomi Y, Tanaka T, Matsushita K, Kawamura T, Kojima T, Aso K, Matsumoto-Okano S, Tsukimi Y.
    Neurogastroenterol Motil; 2020 May 11; 32(5):e13795. PubMed ID: 31970891
    [Abstract] [Full Text] [Related]

  • 18. Involvement of the 5-HT3 receptor in CRH-induce defecation in rats.
    Miyata K, Ito H, Fukudo S.
    Am J Physiol; 1998 May 11; 274(5):G827-31. PubMed ID: 9612262
    [Abstract] [Full Text] [Related]

  • 19. Effect of the 5-hydroxytryptamine3 (5-HT3)-receptor antagonist KB-R6933 on experimental diarrhea models.
    Ozaki A, Yoshidomi M, Sukamoto T.
    Jpn J Pharmacol; 1999 May 11; 80(1):93-6. PubMed ID: 10446763
    [Abstract] [Full Text] [Related]

  • 20. Effect of GK-128 [2-[(2-methylimidazol-1-yl)methyl]-benzo[f]thiochromen-1-one monohydrochloride hemihydrate], a selective 5-hydroxytryptamine3 receptor antagonist, on colonic function in rats.
    Ito C, Isobe Y, Kawamura R, Kiuchi Y, Tsuchida K, Higuchi S.
    J Pharmacol Exp Ther; 1997 Jan 11; 280(1):67-72. PubMed ID: 8996183
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.